Today: 21 January 2026
Subscribe

Marcin Frąckiewicz

CEO of TS2 Space and founder of TS2.tech. Expert in satellites, telecommunications, and emerging technologies, covering trends in space, AI, and connectivity.

Tesla’s Stunning 2025 Comeback: TSLA Stock Soars Amid AI Ambitions, $1 Trillion Musk Bet & EV Wars

Tesla Shareholder Meeting (Nov. 6, 2025): Musk’s Record Pay Plan Approved; Board Re‑Elected as xAI Vote Draws Scrutiny

Austin, Texas — Updated Nov. 6, 2025 TL;DR What passed—and why it matters Musk’s new pay package cleared the vote with a strong majority, delivering a major win for Tesla’s board after months of lobbying large institutions and retail investors. Reuters reports that the plan garnered over 75% support, and shares gained about 2% after hours post‑announcement. Crucially, Tesla’s reincorporation…
6 November 2025
···
TTWO Stock Today (Nov. 6, 2025): Take‑Two Raises Outlook but Pushes ‘GTA 6’ to Nov. 19, 2026; Shares Slip After Hours

TTWO Stock Today (Nov. 6, 2025): Take‑Two Raises Outlook but Pushes ‘GTA 6’ to Nov. 19, 2026; Shares Slip After Hours

Updated: Nov. 6, 2025 — suitable for Google News & Discover Take‑Two (NASDAQ: TTWO) beat revenue expectations and lifted its FY26 outlook, but delayed ‘Grand Theft Auto VI’ to Nov. 19, 2026. Here’s what moved TTWO stock today, the key numbers, guidance, and what to watch next. Key takeaways What happened to TTWO stock today Take‑Two lifted full‑year guidance but…
6 November 2025
·
NuScale Power (SMR) Stock Rockets 14% on Historic 6GW Nuclear SMR Deal — Analysts Weigh In

SMR Stock Today (Nov 6, 2025): NuScale Slides ~14% After Q3 Miss as Fluor Sets Plan to Monetize Stake by Mid‑2026

NuScale Power (NYSE: SMR) fell after hours on November 6, 2025, following a revenue miss and wider‑than‑expected loss. Separately, long‑time backer Fluor agreed to convert and monetize its remaining stake by Q2 2026. Here’s what moved SMR today, the key numbers, and what to watch next. Key takeaways (Nov 6, 2025) SMR stock price today NuScale Power’s stock fell roughly…
6 November 2025
····
Affirm’s Rollercoaster: Profit Milestone, Insider Sell-Off & Big BNPL Bets – What’s Next for AFRM?

AFRM Stock Today (Nov 6, 2025): Affirm Jumps After Q1 FY26 Beat, Extends Amazon Deal, Sets Q2 Revenue Outlook

Published: November 6, 2025 Affirm Holdings (NASDAQ: AFRM) surged in after-hours trading on Thursday after posting stronger‑than‑expected fiscal Q1 2026 results, raising the near‑term outlook and disclosing a multi‑year extension of its U.S. agreement with Amazon. Shares traded around the low‑$70s in the evening session—roughly 9%–11% above the regular‑session close—as investors reacted to the beat‑and‑raise narrative. Benzinga Key Takeaways What…
6 November 2025
···
Airbnb Stock Jumps on AI Upgrades and Travel Boom – Is a Bigger Rally Ahead?

Airbnb (ABNB) Stock Today — November 6, 2025: Shares Jump After Hours as Q3 Revenue Beats and Q4 Outlook Tops Estimates

Summary: Airbnb (NASDAQ: ABNB) closed lower in regular trading but spiked in after-hours after reporting Q3 2025 results that topped revenue expectations and offered an above-consensus Q4 sales outlook. Here’s everything investors need to know today, November 6, 2025. Key takeaways ABNB price action on November 6, 2025 Context: The after-hours bounce reflects investors’ relief on revenue momentum and Q4…
6 November 2025
Alien Probe or Cosmic Relic? Interstellar Comet 3I/ATLAS Baffles Scientists (updated 27.10.2025)

Comet 3I/ATLAS News Roundup (Nov. 6, 2025): China’s Mars Orbiter Images the Interstellar Visitor, JWST Chemistry Update, and How to See It

Comet 3I/ATLAS news roundup — November 6, 2025 Today’s big development: China’s Tianwen‑1 Mars orbiter captured and released new images of the interstellar comet 3I/ATLAS (also cataloged as C/2025 N1), taken from roughly 30 million km away during the comet’s October 3 pass near Mars. China’s state outlets say the sequence shows clear cometary features and marks one of the…
6 November 2025
··
Novo Nordisk (NVO) Stock Tanks as Weight-Loss Empire Faces Boardroom Coup and Fierce Rivalry

NVO Stock Today (Nov 6, 2025): Novo Nordisk volatile as White House pricing deal reshapes GLP‑1 market—what it means for Wegovy, Ozempic and investors

Published: November 6, 2025 TL;DR: Novo Nordisk’s U.S.‑listed shares (NYSE: NVO) swung after the White House announced a pricing-and-access deal with Novo and Eli Lilly that expands Medicare coverage for anti‑obesity drugs and cuts out‑of‑pocket costs. As of 17:51 UTC (12:51 p.m. ET), NVO traded around $47.30, down ~2.4% on the day (intraday range: $46.91–$49.49; volume ~29.3M). The company confirmed…
6 November 2025
··
NYSE Skyrockets to Record Highs as AI Frenzy, Fed Rate Cut Bets Fuel Stock Surge

Why Stocks Are Down Today (Nov. 6, 2025): Tech Sell‑Off, Shutdown Data Void, and Tariff Uncertainty Hit Wall Street

Key takeaways What the market is doing right now Stocks were broadly lower midday Thursday (around 12:30 p.m. ET): the Dow was off by roughly 0.9% (~‑400 to ‑500 points), the S&P 500 down a little over 1%, and the Nasdaq nearly ‑2% as megacaps and chipmakers led declines. A live markets snapshot showed the S&P 500 near 6,710 (‑1.3%),…
6 November 2025
····
Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

Novo Nordisk Stock Today (Nov 6, 2025): NVO steadies as White House GLP‑1 pricing deal lands; $10B Metsera bidding war heats up

Date: Thursday, November 6, 2025Ticker: NVO (NYSE) At a glance: price action and catalysts Novo Nordisk stock traded around $47.36 as of 17:52 UTC, after opening at $47.75 and moving between $46.91–$49.49 on heavy volume. The tape is being driven by two big headlines: (1) a White House pricing agreement that expands access to GLP‑1 drugs across Medicare/Medicaid and a…
6 November 2025
··
Stocks Slip as Tech Wobble Returns; Layoffs Spike and Tariff Showdown Clouds Outlook — Stock Market Today (Nov. 6, 2025)

Dow Jones Today (Nov. 6, 2025): Stocks Slide as Tech Sells Off; Layoffs Surge and FAA Orders Flight Cuts Amid Shutdown

NEW YORK — Thursday, November 6, 2025. U.S. stocks fell sharply in late‑morning trading, with the Dow Jones Industrial Average down more than 400 points (≈0.9%) as renewed selling in mega‑cap tech weighed on the broader market. The Nasdaq led losses at nearly 2%, while the S&P 500 was lower by a little over 1%. Concerns over stretched AI‑linked valuations,…
6 November 2025
···
Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Eli Lilly (LLY) Pops as White House Strikes Obesity-Drug Pricing Deal; New 20% Weight‑Loss Data Fuels Momentum — Today, November 6, 2025

Eli Lilly stock today: drivers, numbers, and what to watch for next. Key takeaways (Nov 6, 2025) Eli Lilly stock today: quote & range As of this afternoon, LLY traded near $935.89, up about 1.1%, with today’s range $916.37–$949.90 and a 52‑week range $624.00–$955.43 (values delayed up to 15 minutes). Reuters 1) The White House’s obesity‑drug deal: lower prices, broader…
6 November 2025
··
Palantir (PLTR) Stock Soars on AI Hype – Is It a Bubble or the Next Tech Giant?

Palantir (PLTR) slips ~5.7% as new marketing & smart‑city deals land — What’s moving the stock today (Nov. 6, 2025)

Updated Nov. 6, 2025 — 16:47 UTC Live price (intraday)As of 16:47 UTC, Palantir shares trade at $177.24, roughly ‑5.7% on the day, after opening at $188.00 and ranging between $176.97–$190.94 so far. Key takeaways What happened today (Nov. 6) 1) Two partnership headlines hit before and during the session 2) Price action in context Today’s decline extends the post‑earnings…
6 November 2025
····
1 … 282 283 284 285 286 … 583

Stock Market Today

  • BXP Stock Slides Amid Valuation Concerns; Cash Flow Estimates Signal Possible Undervaluation
    January 21, 2026, 5:33 AM EST. BXP (NYSE:BXP) shares fell 3.4% in a day and have dropped 10.3% in three months, raising questions about its valuation. The office-focused REIT's recent weak share price contrasts with positive three-year gains, reflecting changing investor sentiment toward office real estate. Trading at $65.63, BXP is priced at a price-to-sales (P/S) ratio of 3x, lower than some fair value models estimate but higher than the broader US Office REIT average of 2.2x. A discounted cash flow (DCF) analysis suggests an even larger undervaluation, placing fair value at $96.46, 32% above current levels. However, recent net income losses and fluctuating asset values highlight risks tied to leasing and refinancing. Investors face a choice between viewing BXP as mispriced or acknowledging potential ongoing pressure in office property markets.
Go toTop